Cell surface complement regulators moderate experimental myasthenia gravis pathology
Article first published online: 5 OCT 2012
Copyright © 2012 Wiley Periodicals, Inc.
Muscle & Nerve
Volume 47, Issue 1, pages 33–40, January 2013
How to Cite
Kusner, L. L., Halperin, J. A. and Kaminski, H. J. (2013), Cell surface complement regulators moderate experimental myasthenia gravis pathology. Muscle Nerve, 47: 33–40. doi: 10.1002/mus.23448
- Issue published online: 15 DEC 2012
- Article first published online: 5 OCT 2012
- Accepted manuscript online: 7 MAY 2012 12:00AM EST
- Manuscript Accepted: 1 MAY 2012
- complement regulatory protein;
- myasthenia gravis;
- neuromuscular junction;
- passive EAMG
Intrinsic mouse complement regulators influence the severity of passively induced experimental acquired myasthenia gravis (EAMG). To assess the potential influence of CD59b in the absence of CD59a background, we used the mCD59ab−/− mouse model to re-evaluate mCD59 in protecting the neuromuscular junction (NMJ).
EAMG was induced with monoclonal antibody to the acetylcholine receptor (AChR) in Daf1−/−, CD59ab−/−, Daf1−/−CD59ab−/−, and wild-type C57Bl/6 mice. Animals were monitored throughout the experiment. Diaphragms were analyzed for NMJ injury.
Daf1−/−CD59ab−/− mice required euthanasia 24 hours after disease induction because of severe weakness. Histological assessment demonstrated reduced AChR density, simplification of synaptic folds, and disrupted mitochondria. CD59ab-deficient mice demonstrated mild weakness and reduction in weight after 24 hours. In contrast, Daf1−/− had more severe weakness at 60 hours. The NMJ of EAMG-induced Daf1−/− and CD59ab−/− mice demonstrated similar AChR density.
NMJs of CD59 and DAF mice are protected from complement-mediated injury of passive EAMG. Muscle Nerve, 2013